1. Access to Early Innovation – The World is our Lab
BIO - June 7, 2016
• Context
• Infectious Diseases
• Early Innovation at ALIOS
• The creativity of diversity
Jos Noben, Head Project Management and Liaison Leader

2. Johnson & Johnson
a market leader in all 3 segments

3. Janssen Research & Development
Johnson &
Johnson
Consumer Pharmaceutical
Marketing &
Commercial
Strategy
Janssen
R&D
Neuro
Sciences
Cardio-
Vascular
and
Metabolic
Diseases
IMUnology ONCOlogy
Infectious
Diseases
Global
Public
Health
Medical Devices &
Diagnostics

4. Infectious Diseases
4
Diagnosis Prevention Treatment Cure
Discover and develop transformational products that
treat, cure and prevent infectious diseases and
change people’s lives worldwide

5. Hepatitis C (HCV)
Hepatitis B (HBV)
Global Health Challenge
16 Percent of All Deaths Are a Result of Infectious Diseases
Our focus is on High Unmet Medical Need to drive Value
Human Immunodeficiency Virus
(HIV)
Tuberculosis (TB)
Respiratory Syncytial Virus
(RSV)
Influenza
Pathogens of
Global Concern
Ebola, Dengue, Zika
Hepatitis Respiratory
HIV

6. Raritan, NJ
Titusville, NJ
Malvern, PA
Spring House, PA
Boston, MA
Beerse, Belgium
Leiden, The Netherlands
High Wycombe, UK
London, UK
La Jolla, CA
San Francisco, CA
Beijing, China
Shanghai,
China
Cape Town, SA

7. JOHNSON & JOHNSON ANNOUNCES COMPLETION OF ALIOS BIOPHARMA ACQUISITION
-- Further Strengthens Existing Pipeline to Address Infectious Diseases --
New Brunswick, 7 November 2014 – Johnson & Johnson today announced the completion of the
acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused
on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in
cash.
With this acquisition complete, Alios BioPharma will now become part of the infectious diseases
therapeutic area of the Janssen Pharmaceutical Companies of Johnson & Johnson.
- Nucleoside Technology Platform
- Compatible portfolio of lead compounds in Early Development  Products
- Biotech minded development operations  Process
- Key experts  People

8. About me, and why I’m here
• Studies
– Biology/Virology/Management (LUC, KUL, Vlerick)
– Arts (Maastricht, Antwerp, Urciers)
• Janssen R&D
– Discovery Research, Project Management in Clinical Operations and
Manufacturing (Sporanox)
• Tibotec
– Biotech company focused on Infectious Diseases
• Janssen Infectious Diseases R&D
– TAL Project Management Infectious Diseases
 Liaison Leader for Alios and Janssen

9. 9
Goal: A fully integrated IDV Tx R&D
JNJ / Alios / Janssen IDentity
• Balanced groups of R&D experts in San Francisco, Beerse,
Shanghai and Titusville-Raritan, working together as ONE
globally.
• Entrepreneurial Biotech model and culture (a blend of past
and future)
• FOCUS on efficiency and collaboration to deliver on the
promise
• The combination of Janssen and Alios presents a great
pipeline with future and potential
• Applying J&J Key Principles and Credo Values

10. The creativity of diversity
In our worldwide laboratory